Ridaforolimus

Ridaforolimus (MK-8669) is a potent and selective mTOR inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells[1].

Product Specifications

CAS Number

[572924-54-0]

Product Name Alternative

MK-8669; Deforolimus; AP23573

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Bacterial; mTOR

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Deforolimus.html

Purity

99.75

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C([C@](O[C@]1([H])C[C@@H](/C(C)=C/C=C/C=C/[C@H]2C)OC)([C@@H](CC1)C)O)=O)N(CCCC3)[C@]3([H])C(O[C@](CC([C@@H](/C=C([C@H]([C@H](C([C@H](C)C2)=O)OC)O)\C)C)=O)([H])[C@H](C)C[C@H](CC[C@H]4OP(C)(C)=O)C[C@H]4OC)=O

Molecular Formula

C53H84NO14P

Molecular Weight

990.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Rivera VM, et al. Deforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011 Jun;10 (6) :1059-71.|[2]Brandt M, et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. Cell Metab. 2018 Jan 9;27 (1) :118-135.e8.